10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one | 733011-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
• 英文别名: 1,3,10-trihydroxy-5-(3,7,11-trimethyldodecyl)-11H-benzo[b][1,4]benzodiazepin-6-one
• CAS: 733011-52-4
• 化学式: C₂₈H₄₀N₂O₄
• 分子量: 468.637
• InChiKey: DSCWMFCRNDMRKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  93
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  diazepinomicin 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 生成 10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
  参考文献：
  名称：

  TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO

  摘要：

  该发明涉及一种评估候选分子化疗潜力的方法。在评估候选分子时，将测试候选分子抑制癌细胞体外生长的能力；结合由癌细胞产生的细胞受体，其中所述受体，如外周苯二氮卓受体，由所述癌细胞产生的数量比正常细胞多；并抑制MAPK通路中至少一个蛋白质成员的活性。该发明还涉及二苯二氮卓酮类似物及其衍生物。

  公开号：

  US20090062255A1

文献信息

• TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO
  申请人：GOURDEAU Henriette

  公开号：US20090062255A1

  公开（公告）日：2009-03-05

  The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof.

  该发明涉及一种评估候选分子化疗潜力的方法。在评估候选分子时，将测试候选分子抑制癌细胞体外生长的能力；结合由癌细胞产生的细胞受体，其中所述受体，如外周苯二氮卓受体，由所述癌细胞产生的数量比正常细胞多；并抑制MAPK通路中至少一个蛋白质成员的活性。该发明还涉及二苯二氮卓酮类似物及其衍生物。
• [EN] METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE DIBENZODIAZÉPINONES DE FARNÉSYLE
  申请人：AMO PHARMA LTD

  公开号：WO2021243171A1

  公开（公告）日：2021-12-02

  The present invention is directed to synthetic means for producing farnesyl dibenzodiazepinone compounds, including AMO-01.

  本发明旨在提供合成手段以生产法尼酰二苯并二氮杂环己酮类化合物，包括AMO-01。
• Farnesyl dibenzodiazepinone and processes for its production
  申请人：McAlpine James B.

  公开号：US20080199940A1

  公开（公告）日：2008-08-21

  This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

  本发明涉及一种新型的法尼醇基二苯并二氮杂环酮，命名为ECO-04601，其药物可接受的盐和衍生物，以及获得这种化合物的方法。获得ECO-04601化合物的一种方法是通过培养一种新的微单孢菌株Micromonosporasp. 046-ECO11; 另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。本发明还涉及Micromonosporasp.株046-ECO11的使用，以及ECO-04601及其药物可接受的盐和衍生物作为药物的使用，特别是作为癌细胞生长抑制剂，细菌细胞生长抑制剂，哺乳动物脂氧合酶以及包含ECO-04601或其药物可接受的盐或衍生物的药物组合物。最后，本发明涉及新的多核苷酸序列及其编码的蛋白质，这些蛋白质参与ECO-04601的生物合成。
• FARNESYL DIBENZODIAZEPINONE AND PROCESSES FOR ITS PRODUCTION
  申请人：ZAZOPOULOS Emmanuel

  公开号：US20090263886A1

  公开（公告）日：2009-10-22

  This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

  本发明涉及一种新型的法尼酰化二苯并二氮平酮，名为ECO-04601，其药学上可接受的盐和衍生物，以及获得这种化合物的方法。获得ECO-04601化合物的一种方法是通过培养一种新的微单孢菌株Micromonosporasp.，046-ECO11；另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。本发明还涉及Micromonosporasp.株系046-ECO11的使用及其药学上可接受的盐和衍生物作为药物，特别是它们作为抑制癌细胞生长、细菌细胞生长、哺乳动物脂氧合酶的药物的使用，以及包含ECO-04601或其药学上可接受的盐或衍生物的药物组合物。最后，本发明涉及新的多核苷酸序列及其编码的蛋白质，这些蛋白质参与ECO-04601的生物合成。
• Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
  申请人：McAlpine B. James

  公开号：US20060079509A1

  公开（公告）日：2006-04-13

  The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.

  本发明涉及由式 I 表示的具有生物活性的二苯并二氮杂卓类似物、生产它们的方法、包含它们的药物组合物以及治疗肿瘤疾病的方法。